Vistusertib (AZD2014)

For research use only. Not for use in humans.

Catalog No.S2783

39 publications

Vistusertib (AZD2014) Chemical Structure

Molecular Weight(MW): 462.54

Vistusertib (AZD2014) is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (α/β/γ/δ). AZD2014 showed no or weak binding to the majority of kinases when tested at 1 μM.

Size Price Stock Quantity  
USD 170 In stock
USD 270 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Vistusertib (AZD2014) has been cited by 39 publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Vistusertib (AZD2014) is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (α/β/γ/δ). AZD2014 showed no or weak binding to the majority of kinases when tested at 1 μM.
Targets
mTOR [1]
(Cell-free assay)		 P-Akt (S473) [1]
(Cell-free assay)		 pS6 (S235/236) [1]
(Cell-free assay)
2.8 nM 80 nM 200 nM
In vitro

AZD2014 is a close analogue of AZD8055 and a selective inhibitor of mTOR kinase. AZD2014 has greater inhibitory activity against mTORC1 compared to rapamycin: AZD2014 decreases p4EBP1 Thr37/46, inhibits the translation initiation complex and decreases overall protein synthesis while rapamycin has no effect. AZD2014 also inhibits the mTORC2 biomarkers pAKTSer473 and pNDRG1Thr346. AZD2014 has broad antiproliferative activity across multiple tumour cell lines. In particular, AZD2014 induces growth inhibition and cell death in breast cancer cell lines, including ER+ cell lines with acquired resistance to hormone therapy. [1]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 cells NULueVRLTnWwY4Tpc44h[XO|YYm= NYHFPWpCUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBHVEGJLYTh[4dm\CCvVF;SJEgyOzZ{IITvJFI2PDlrIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyxiSVO1NF0zNjhibl2= MkH1NlM{PzV5OUO=
human MDA-MB-468 cells M{HIOWZ2dmO2aX;uJIF{e2G7 MYeyJIg> NIXsVIJKdmirYnn0bY9vKG:oIH3UU3JEOiCrbjDoeY1idiCPRFGtUWIuPDZ6IHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IGPldlQ4OyCjZoTldkAzKGi{czygTWM2OD1yLkC4JO69VQ>? Ml[yNlM{PzV5OUO=
human MDA-MB-468 cells M2S4T2Z2dmO2aX;uJIF{e2G7 NVHZV5Q1OiCq NUDz[FRUUW6qaXLpeIlwdiCxZjDtWG9TSzFiaX6gbJVu[W5iTVTBMW1DNTR4ODDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheFN4IIDoc5NxcG:{eXzheIlwdiCjdDDT[ZIzOzVxMkO2JIFnfGW{IEKgbJJ{NCCLQ{WwQVAvOiEQvF2= NVf0W2EyOjN|N{W3PVM>
human MCF7 cells NH:3d2tHfW6ldHnvckBie3OjeR?= MkfWTY5pcWKrdHnvckBw\iCvVF;SR|EhcW5iaIXtZY4hVUOINzDj[YxteyC6ZX7v[5Ji\nSnZDDtc5V{\SCjc4Pld5Nm\CCjczDtc4R2dGG2aX;uJJN2[nO2cnH0[S=> NFe4bYYzOzN5NUe5Ny=>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-4EBP1 / 4EBP1 / p-S6K / S6K / p-AKT S473 / AKT; 

PubMed: 25628925     


Biochemical activity of AZD2014 and rapamycin in blocking mTORC1 and mTORC2 signaling. HCC cells were treated with DMSO or increasing concentrations of AZD2014 or rapamycin for 1 hour before lysis and immunoblotting.

p-mTOR(S2448) / mTOR / p-S6(235/236) / S6; 

PubMed: 26176608     


AZD2014 and rapamycin inhibited mTOR signaling in A549 cells as shown by the decreased phosphorylation of mTORand S6 after treatment for 24h.

25628925 26176608
Immunofluorescence
E-cadherin / Vimentin ; 

PubMed: 25628925     


Immunofluorescence staining in Huh-7 and SMMC-7721 cells. bars, 30 μm

25628925
Growth inhibition assay
Cell viability; 

PubMed: 26219339     


Dose-response curve for AZD2014 was determined for NF2-deficient primary (MN521, MN527, MN580) and immortalized (Ben-Men-1) meningioma cells lines, as well as primary (AC028) and immortalized arachnoid (AC007) cell lines. AZD2014 in a 10 point, 4-fold serial dilution series (0-20μM).

26219339
In vivo AZD2014 induces tumour growth inhibition against several xenograft models including a human primary explant model of ER+ breast cancer refractory to tamoxifen. The antitumour activity is associated with modulation of both mTORC1 and mTORC2 substrates. [1]

Protocol

Solubility (25°C)

In vitro DMSO 38 mg/mL (82.15 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 462.54
Formula

C25H30N6O3
CAS No. 1009298-59-2
Storage powder
in solvent
Synonyms N/A
Smiles CNC(=O)C1=CC=CC(=C1)C2=CC=C3C(=N2)N=C(N=C3N4CCOCC4C)N5CCOCC5C

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02780830 Withdrawn Drug: AZD2014|Drug: Ibrutinib Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Module 1: Non-GCB Diffuse Large B-Cell Lymphoma AstraZeneca June 2016 Phase 1
NCT02730923 Recruiting Drug: AZD2014|Drug: Anastrozole Endometrial Carcinoma|Metastatic Carcinoma|Hormone Receptor Positive Tumor Centre Leon Berard April 2016 Phase 1|Phase 2
NCT02619864 Active not recruiting Drug: AZD2014 Glioblastoma Multiforme Canadian Cancer Trials Group|AstraZeneca January 13 2016 Phase 1
NCT02599714 Active not recruiting Drug: AZD2014|Drug: Palbociclib|Drug: Fulvestrant Advanced and Metastatic Breast Cancer AstraZeneca December 7 2015 Phase 1
NCT02752204 Active not recruiting Drug: AZD 2014|Drug: Rituximab Diffuse Large B-Cell Lymphoma University of Birmingham|Bloodwise|AstraZeneca|Cancer Research UK October 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am looking for a i.p. or i.v. formula of AZD2014. Any suggestion?

  • Answer:

    S2783 AZD2014 can be dissolved in 5% DMSO/30% PEG 300/ddH2O at 5 mg/ml as a clear solution for I.P. use.

selleck catalog

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

  • Pan mTOR inhibitor

    KU-0063794 : mTORC1 and mTORC2, IC50=~10 nM.

  • Most Potent mTOR Inhibitor

    Rapamycin (Sirolimus) : mTOR, IC50=~0.1 nM.

  • FDA-approved mTOR Inhibitor

    Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).

  • Newest mTOR Inhibitor

    XL388 New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

Related mTOR Products

  • MHY1485 New

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021) New

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.

  • Dorsomorphin (Compound C) New

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

  • Temsirolimus (CCI-779)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • Sapanisertib (MLN0128)

    Sapanisertib (INK 128, MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

Tags: buy Vistusertib (AZD2014) | Vistusertib (AZD2014) supplier | purchase Vistusertib (AZD2014) | Vistusertib (AZD2014) cost | Vistusertib (AZD2014) manufacturer | order Vistusertib (AZD2014) | Vistusertib (AZD2014) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID